WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--ISENTRESS® (raltegravir), Merck's first-in-class HIV-1 integrase inhibitor, suppressed HIV-1 viral load and increased CD4 cell counts through 48 weeks of combination therapy with other anti-HIV medicines compared to placebo in combination with other anti-HIV medicines in HIV-infected patients with triple-class resistant virus failing current therapy. These results from two pivotal Phase III studies of 699 treatment-experienced patients who were failing other antiretroviral therapies (ARTs) were published today in the New England Journal of Medicine.
